Bibliography
(1) Steegmann JL et al. 2016. European Leukemia Net Recommendations for
the management and avoidance of adverse events of treatment in CML
(ocular events chapter). Leukemia; 30(8): 1648–1671
(2) Davis ME et al. 2016. Ocular toxicity of TKIs. Oncol Nurs Forum;
43(2): 235-243
(3) Kwon SI, Lee DH, Kim YJ. 2008. Optic disc edema as a possible
complication of Imatinib mesylate (Gleevec). Jpn J Ophthalmol; 52(4):
331–333
(4) DeLuca C, Shenouda-Awad N, Haskes C, Wrzesinski S. 2012. Imatinib
mesylate (Gleevec) induced unilateral optic disc edema. Optom Vis
Sci; 89(10): e16–e22
(5) Napolitano M, Santoro M, Mancuso S, Carlisi M, Raso S, Tarantino G,
Accurso V, Siragusa S. 2017.
Late onset
of unilateral optic disk edema secondary to treatment with imatinib
mesylate. Clin Case Rep; 5(10): 1573–1575
(6) Kheir WJ, Sniegowski MC, El-Sawy T, Li A, Esmaeli B. 2014.
Ophthalmic complications of targeted cancer therapy and recently
recognized ophthalmic complications of traditional chemotherapy. Survey
of Ophthalmology; 59:498–502
(7) Renouf DJ, Velazquez JP, Simpron, Siu LL, Bedard PL. 2012. Ocular
toxicity of targeted therapies. Journal of Clinical Oncology;
30:3277–3286
(8) Breccia M et al. 2008. Ocular side effects in CML patients treated
with Imatinib. Leuk Res; 32(7):1022-5
(9) Govind BK et al. 2007. IM-induced optic neuritis in a patient of
chronic myeloid leucemia. Int Ophthamol; 27:43-4
(10) Fu C et al. 2017. Ocular toxicities associated with targeted
anticancer agents: an analysis of clinical data with management
suggestions. Oncotarget, 8, (35): 58709-58727
(11) Moore DC et al. 2018. Nilotinib-induced ocular toxicity: a case
report. Am J Ther; 25(5):e570-e571
(12) Sotelo-Monge K et al. 2015. Ocular neuropathy secondary to
dasatinib in the treatment of CML case. Saudi J Ophtalmology; 29(3):
227-231
(13) Cortes JE et al. 2018. Management of adverse events associated with
bosutinib treatment of CP-CML: expert pad review. J HematolOncol;
27;11(1):143
(14) A multicentre phase 3 open-label study of Bosutinib versus Imatinib
in adult patients with newly diagnosed CP-CML. ClinicalTrials.gov. URL:
https://clinicaltrials.gov/ct2/show/NCT02130557
(15) Cortes JE et al. 2018. Bosutinib versus Imatinib for Newly
Diagnosed Chronic Myeloid Leukemia: Results From the Randomized BFORE
Trial. J ClinOncol; 20;36(3):231-237